BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 30, 2003
View Archived Issues
Beneficial effects reported for duloxetine in primary fibromyalgia
Read More
LJP-394 well tolerated in SLE patients with renal disease
Read More
Milnacipran as a potential therapy for FMS
Read More
Immunomodulatory effects of OM-89 in rheumatoid arthritis patients
Read More
Studies on lumiracoxib in rheumatoid arthritis presented at ACR meeting
Read More
Immunomodulating activity reported for LymphoStat-B in monkeys and SLE patients
Read More
Sankyo describes the isolation of a 2'-PDE inhibitor with utility in viral infections
Read More
First North American trial of Adhibit
Read More
Levaquin approved for five-day treatment of CAP
Read More
Millennium and Bayer alliance concludes
Read More
New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis
Read More
Indian group identifies new antiallergic/antiasthmatic agents
Read More
Servier team presents new 5-HT2C antagonists for anxiety and other disorders
Read More
Apotex researchers prepare and test new factor XIIIa inhibitors
Read More
Two series of PDE7 inhibitors and their use presented by Warner-Lambert (Pfizer) scientists
Read More
Novel HIV integrase inhibitors claimed by Merck
Read More
Novartis describes new CCR3 antagonists with utility in asthma therapy
Read More
Sankyo intensifies development of anticancer drugs
Read More
Sifrol approved for the treatment of Parkinson's disease
Read More
Raptiva approved for chronic, moderate to severe plaque psoriasis
Read More
Approvable letter received for Ariflo
Read More
Canadian approval for Gleevec for newly diagnosed Ph+ CML
Read More
European enrollment commences in phase II trial for DAC:GLP-1
Read More
Development of KW-6002 temporarily suspended
Read More
Prodrugs of CO/CO2 associated with clinical and radiographic improvement in arthritis
Read More
Targeted therapy of AML with anti-FLT3 antibody under evaluation
Read More
Anticytokine drug in development at Kowa for oral therapy of arthritis
Read More
Microbially produced inhibitor of bacteria-specific enzyme discovered
Read More